-
SPECIAL REPORTS
Special Reports
- Vulnerable Consumers
- Delivering water in the 21st century
- Reviewing Europe's alcohol harm strategy
- Greening the CAP
- Water Policy
- Broadband: driving recovery?
- Data protection
- ICT: Fuelling the economy
- Europe's electricity grids: Joining up the dots
- Countdown to the European Citizens' Initiative (ECI)
- Innovation and the Digital Economy
- Cloud Computing
- Jobs and Growth
- Air Quality
- Solar Power
- Resource efficiency: towards a circular economy
- Small Business:driving EU growth?
- SME's Access to Finance
- Rural Energy
- EU-Ukraine Relations
- EU budget 2014-2020
- European Business Summit 2011
- General
- Wind Energy
- Raw Materials
- Small Business Act Review
- Food & Responsible Marketing
- Europe's Regions in 2020
EU news & policy debates
- across languages -
- across languages -
Click here for EU news »
x
EU launches international research programme to fight AIDS, malaria and tuberculosis
Published 23 April 2002 - Updated 29 January 2010
At a conference organised by the Spanish Presidency in Barcelona on 19 April 2002, Commissioner Philippe Busquin launched the first phase of the "European-Developing Countries Clinical Trials Programme" (EDCTP). The programme aims to encourage research on HIV/AIDS, malaria and tuberculosis, in order to speed up the development and production of vaccines and drugs.
Positions:
The European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomed this initiative to increase the effectiveness of Europe’s investment in clinical trials for poverty-related diseases.
Background:
The EDCTP is one of the pillars of the EU's action plan against poverty-related diseases, which includes a set of trade, development and research measures.
Fourteen EU countries and Norway will co-ordinate their national research efforts through a joint platform, in full partnership with the developing countries. The programme will also:
- sponsor clinical trials in public-private partnerships across Africa;
- enhance African countries' development and production capabilities;
- identify the most promising vaccine and drug candidates and pool investments for their development at clinical level;
- build capacities for clinical development of drugs and vaccines in the south of the world, through support for infrastructures, training, etc.;
- sponsor clinical trials in Africa in public private partnerships with industry;
The Commission proposes to allocate € 200 million to the initiative over five years.
Commissioner Philippe Busquin commended the strong record of European research institutes in researching poverty-related diseases, and their long tradition of bilateral co-operation with developing countries.
Advertising
Advertising
Stockholm
Théâtre National - Brussels
Maastricht
31 May 2012 - 01 June 2012:
Maastricht